Clinical Trials List
2025-07-01 - 2029-09-30
Phase I
Recruiting2
ICD-10C69.40
Malignant neoplasm of unspecified ciliary body
ICD-10C69.41
Malignant neoplasm of right ciliary body
ICD-10C69.42
Malignant neoplasm of left ciliary body
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9190.0
Malignant neoplasm of eyeball, except conjunctiva, cornea, retina and choroid
-
Trial Applicant
Boehringer Ingelheim
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/03/01
Investigators and Locations
Co-Principal Investigator
- Hsiang-Fong Kao Division of Hematology & Oncology
- TSUNG-HAO LIU Division of Hematology & Oncology
- 廖唯昱 Division of General Internal Medicine
- 吳宗哲 Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- YU-YUN SHAO Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- Chiun Hsu Division of Hematology & Oncology
- 楊景堯 Division of General Internal Medicine
- 廖斌志 Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- 許嘉林 Division of General Internal Medicine
- HUAI-CHENG HUANG Division of Hematology & Oncology
- YEN-TING LIN Division of General Internal Medicine
- SHIH-HUNG YANG 無
- Jih-Hsiang Lee Division of Hematology & Oncology
- 吳尚俊 Division of General Internal Medicine
- Ying-Chun Shen Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chien-An Liu Division of Radiology
- 唐振育 Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
- 邱乃祈 Division of Radiology
- San-Chi Chen Division of Hematology & Oncology
- 姜乃榕 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
97 participants